Pipeline

Dystrogen Therapeutics is focused on the development of Cell Therapy Platform.

Program Indications Phase

DT-DEC01

DMD

DT-200

Neuro-Degenerative

DT-201

Sarcopenia

DT-202

Graft-vs-Host Disease

Candidates developed under Chimeric Cell platform: